VRDN — Viridian Therapeutics, Inc. stock price, charts and financials
QT46Viridian Therapeutics, Inc.Viridian Therapeutics, Inc. (NASDAQ: VRDN) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
Latest market price
21.93
-0.51-2.27%
News
Down 2.3% — Viridian Therapeutics: Two Products, One Commercial Buildout (seekingalpha.com).
Medium confidence
TA
Loading chart...
Snapshot
| Index | - | P/E | - | EPS (ttm) | -17.07 | Insider Own | 25.32% | Shs Outstand | 113.29M | Perf Week | -1.62% |
| Market Cap | 2.48B | Forward P/E | - | EPS next Y | -2.59 | Insider Trans | 4.07% | Shs Float | 105.16M | Perf Month | -8.36% |
| Enterprise Value | 1.75B | PEG | - | EPS next Q | -0.99 | Inst Own | - | Short Float | 18.55% | Perf Quarter | 31.24% |
| Income | -343.00M | P/S | 34.99 | EPS this Y | 76.97% | Inst Trans | - | Short Ratio | 10.11 | Perf Half Y | -20.92% |
| Sales | 71.00M | P/B | 3.75 | EPS next Y | 34.08% | ROA | -35.27% | Short Interest | 19.51M | Perf YTD | -29.53% |
| Book/sh | 5.84 | P/C | 2.53 | EPS next 5Y | - | ROE | -61.35% | 52W High | 34.29 -36.05% | Perf Year | 17.52% |
| Cash/sh | 8.67 | P/FCF | - | EPS past 3/5Y | - | ROIC | -39.18% | 52W Low | 13.18 66.39% | Perf 3Y | 23.55% |
| Dividend Est. | - | EV/EBITDA | - | Sales past 3/5Y | 228.66% 134.56% | Gross Margin | 99.55% | Volatility | 4.82% 3.62% | Perf 5Y | 86.48% |
| Dividend TTM | - | EV/Sales | 24.58 | EPS Y/Y TTM | 15.33% | Oper. Margin | -569.68% | ATR (14) | 0.93 | Perf 10Y | -81.61% |
| Dividend Ex-Date | - | Quick Ratio | 16.95 | Sales Y/Y TTM | - | Profit Margin | -544.06% | RSI (14) | 46.27 | Recom | 2.13 |
| Dividend Gr. 3/5Y | - | Current Ratio | 16.95 | EPS Q/Q | -5.00% | SMA20 | -4.84% | Beta | 1.08 | Target Price | 36.14 |
| Payout | 0.00% | Debt/Eq | 0.07 | Sales Q/Q | - | SMA50 | 1.58% | Rel Volume | 0.67 | Prev Close | 22.44 |
| Employees | 252 | LT Debt/Eq | 0.07 | Earnings | Nov 04 | SMA200 | -6.48% | Avg Volume | 1.88M | Price | 21.93 |
| IPO Date | Jun 18, 2014 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -1.48% 403.87% | Net Debt/EBITDA | -0.21 | Volume | 1,268,415 | Change | -2.27% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Aug-07-26 | Reiterated | Truist Securities | Buy | $38 → $39 |
| Aug-07-26 | Reiterated | RBC Capital | Outperform | $34 → $36 |
| Jun-30-26 | Reiterated | Goldman Sachs | Buy | $35 → $39 |
| Jun-30-26 | Reiterated | Truist Securities | Buy | $35 → $38 |
| Jun-29-26 | Reiterated | Truist Financial | Buy | $33 → $35 |
| Jun-29-26 | Upgrade | Wells Fargo | Equal Weight → Overweight | $31 |
| May-15-26 | Reiterated | Evercore ISI Group | Outperform | $45 → $26 |
| May-13-26 | Reiterated | Stifel Nicolaus | $48 → $39 | |
| May-06-26 | Reiterated | RBC Capital | Outperform | $45 → $34 |
| Apr-21-26 | Reiterated | Truist Securities | Buy | $36 → $33 |
Latest News· Times ET
Sep-17-26
Sep-08-26
Sep-08-2604:30AM
12:49AM
Sep-03-26
Sep-02-26
Sep-02-2612:00PM
Aug-26-26
Aug-26-2611:34PM
Aug-23-26
Aug-23-2611:54PM
Aug-07-26
Aug-07-2605:27AM
Aug-06-26
Aug-06-2611:02AM
04:00AM
Aug-03-26
Aug-03-2612:16AM
Jul-01-26
Jul-01-2602:21AM
Jun-30-26
Jun-30-2604:30AM
Jun-29-26
Jun-29-2610:12AM
Company
Viridian Therapeutics, Inc. is a biotechnology firm committed to creating therapies for patients afflicted by serious illnesses. Its primary development efforts include VRDN-001, a humanized monoclonal anti-IGF-1R antibody currently advancing through Phase 1/2 clinical trials for thyroid eye disease (TED). The company's portfolio also features VRDN-002, an IGF-1R antibody undergoing Phase 1 clinical evaluation, alongside VRDN-003, a therapeutic antibody also designed to target IGF-1R for TED. Established in 2006, this Waltham, Massachusetts-based firm previously operated as Miragen Therapeutics, Inc., before changing its name to Viridian Therapeutics, Inc. in January 2021.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | FY 2017 12/31/2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 71 | 0 | 0 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 0 | 0 | 0 | — | — | — | — | — | — | |
| Gross Profit | 71 | 0 | 0 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 95 | 61 | 95 | — | — | — | — | — | — | |
| Research and Development | 339 | 238 | 160 | — | — | — | — | — | — | |
| Other Operating Expense | 0 | 0 | 0 | — | — | — | — | — | — | |
| Operating Income | -363 | -299 | -254 | — | — | — | — | — | — | |
| Interest Expense | 5 | 3 | 2 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 26 | 32 | 19 | — | — | — | — | — | — | |
| Net Income Before Taxes | -343 | -270 | -238 | — | — | — | — | — | — | |
| Income Taxes | 0 | 0 | 0 | — | — | — | — | — | — | |
| Consolidated Net Income | -343 | -270 | -238 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | -343 | -270 | -238 | — | — | — | — | — | — | |
| Net Income | -343 | -270 | -238 | — | — | — | — | — | — | |
| EPS (Recurring) | -3.32 | -3.98 | -5.31 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -3.32 | -3.98 | -5.31 | — | — | — | — | — | — | |
| EPS (Diluted) | -3.32 | -3.98 | -5.31 | — | — | — | — | — | — | |
| EBITDA | -337 | -266 | -235 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 37.26 | — | — | — | — | — | — | — | — | |
| Gross Margin | 100.00 | — | — | — | — | — | — | — | — | |
| Operating Margin | -511.27 | — | — | — | — | — | — | — | — | |
| Net Margin | -483.10 | — | — | — | — | — | — | — | — | |
| Shares Outstanding | 85 | 68 | 45 | — | — | — | — | — | — | |
| Market Capitalization | 2,645 | 1,304 | 980 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Tousignant Jennifer | Chief Legal Officer | Aug 19 '26 | Option Exercise | 14.41 | 10,000 | 144,100 | 10,000 | Aug 20 |
| Tousignant Jennifer | Chief Legal Officer | Aug 19 '26 | Sale | 24.50 | 10,000 | 245,000 | 0 | Aug 20 |
| Tripuraneni Radhika | Chief Medical Officer | Aug 14 '26 | Option Exercise | 13.21 | 40,000 | 528,400 | 40,000 | Aug 18 |
| Fairmount Funds Management LLC | director, 10 percent owner: | May 11 '26 | Buy | 17.00 | 1,176,470 | 19,999,990 | 5,090,928 | May 13 |
| Tousignant Jennifer | Chief Legal Officer | Mar 03 '26 | Option Exercise | 0.00 | 5,169 | 0 | 5,169 | Mar 04 |
| Harmon Seth | Chief Financial Officer | Mar 03 '26 | Option Exercise | 0.00 | 6,267 | 0 | 9,881 | Mar 04 |
| Beetham Thomas W. | Chief Operating Officer | Mar 03 '26 | Option Exercise | 0.00 | 9,409 | 0 | 16,409 | Mar 04 |
| Mahoney Stephen F. | President and CEO | Mar 03 '26 | Option Exercise | 0.00 | 18,357 | 0 | 40,757 | Mar 04 |
| Tousignant Jennifer | Chief Legal Officer | Dec 31 '25 | Sale | 31.16 | 2,272 | 70,796 | 0 | Jan 02 |
| Fairmount Funds Management LLC | director, 10 percent owner: | Oct 23 '25 | Buy | 22.00 | 454,545 | 9,999,990 | 3,914,458 | Oct 27 |
| Fairmount Funds Management LLC | director, 10 percent owner: | Jun 10 '25 | Option Exercise | 12.31 | 12,500 | 153,875 | 3,459,913 | Jun 11 |
| Fairmount Funds Management LLC | director, 10 percent owner: | Jun 09 '25 | Option Exercise | 7.80 | 1,600 | 12,480 | 3,447,413 | Jun 11 |
| Beetham Thomas W. | Chief Operating Officer | Sep 27 '24 | Buy | 23.41 | 5,000 | 117,050 | 6,000 | Sep 30 |
| Mahoney Stephen F. | President and CEO | Sep 27 '24 | Buy | 23.33 | 21,400 | 499,262 | 21,400 | Sep 30 |
| Fairmount Funds Management LLC | director, 10 percent owner: | Sep 13 '24 | Buy | 18.75 | 1,600,000 | 30,000,000 | 3,445,813 | Sep 17 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.